glp 1 receptor antagonist drugs GLP-1 Agonists as Treatments for Type 2 Diabetes Glucagon-like peptide-1 receptor agonists and
Description
GLP-1 medications decreased fatal stroke by 26% and non-fatal stroke by 13% 16

95% CI 12.93, 2.25), and metformin (WMD: 4.77

AprilJune 2016

In the real-world setting, persistence with GLP-1 RA therapy has been found to range between 40% and 60% and between 34% and 67% at 180 and 360 days, respectively [23,24,25]

These findings suggest that SGLT2i therapy may overall have more benefit than GLP-1 RA therapy in type 1 diabetes

doi: 10.1111/dom.13025
